CABANA trial: "beauty is in the eye of the beholder".
David BricenoPrasant MohantyLuigi Di BiaseJorge RomeroDomenico Giovanni Della RoccaChintan TrivediSanghamitra MohantyAndrea NatalePublished in: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2019)
The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- left atrial appendage
- oral anticoagulants
- cardiac arrest
- phase iii
- study protocol
- direct oral anticoagulants
- clinical trial
- phase ii
- heart failure
- percutaneous coronary intervention
- cardiopulmonary resuscitation
- randomized controlled trial
- stem cells
- coronary artery disease
- open label
- bone marrow
- emergency department
- mesenchymal stem cells
- left ventricular
- replacement therapy